Scholarlink

<p>Incretin-based therapies represent highly effective treatments that, in addition to promoting substantial weight loss and improving glycemic control, provide numerous other cardiometabolic benefits. As a&#xa0;result, associated comorbidities can be positively influenced and morbidity as well as mortality can be reduced. Data from animal studies are not directly transferable to humans, and the healthy thyroid does not constitute a&#xa0;target for incretin therapy in humans. Treatment with incretin-based therapies is not associated with clinically relevant increases in calcitonin. Current evidence does not support a&#xa0;causal relationship between incretin therapy and the risk of thyroid cancer in humans. Furthermore, the absolute risk of thyroid cancer is low and is outweighed by the expected benefits of such pharmacotherapy, particularly in patients with high cardiometabolic risk. Incretin therapy should, however, be avoided in individuals with a&#xa0;personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type&#xa0;2. Routine monitoring of calcitonin is not recommended.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inkretinmimetika und Schilddrüsenkrebs: Gibt es ein Risiko?

  • 期刊论文

  • 发表日期：

    2026年2月26日

查看全文
  • Verena Parzer

摘要

Incretin-based therapies represent highly effective treatments that, in addition to promoting substantial weight loss and improving glycemic control, provide numerous other cardiometabolic benefits. As a result, associated comorbidities can be positively influenced and morbidity as well as mortality can be reduced. Data from animal studies are not directly transferable to humans, and the healthy thyroid does not constitute a target for incretin therapy in humans. Treatment with incretin-based therapies is not associated with clinically relevant increases in calcitonin. Current evidence does not support a causal relationship between incretin therapy and the risk of thyroid cancer in humans. Furthermore, the absolute risk of thyroid cancer is low and is outweighed by the expected benefits of such pharmacotherapy, particularly in patients with high cardiometabolic risk. Incretin therapy should, however, be avoided in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Routine monitoring of calcitonin is not recommended.